Clinical outcomes of ultrathin strut biodegradable polymer-coated everolimus-eluting stent in patients with coronary artery disease

BACKGROUND: Evermine ۵۰™ (Meril Life Sciences Pvt. Ltd., India) everolimus-eluting stent system (EES) is a novel ultrathin strut (۵۰ µm) cobalt-chromium coronary drug-eluting stent (DES) platform with biodegradable polymer coating. The Evermine ۵۰ EES-KLES study aimed to evaluate the Evermine ۵۰ EES in terms of ۲۴-month clinical safety and performance in patients with coronary artery disease (CAD).METHODS: This retrospective study consisted of ۱۷۱ patients (۲۵۸ lesions) implanted with Evermine ۵۰ EES for managing CAD. We analyzed the major adverse cardiac events (MACE) incidence, defined as a composite of cardiac death, myocardial infarction, and ischemia-driven target lesion revascularization (ID-TLR) at ۶-, ۱۲-, and ۲۴-month follow-up.RESULTS: A total of ۱۷۱ patients were included with a mean age of ۵۷.۸۵ ± ۱۰.۰۵ years, of which, ۱۳۹ (۸۱.۲۹%) were men, ۶۹ (۴۰.۳۵%) were hypertensive, and ۷۰ (۴۰.۹۴%) were diabetic. The incidence of MACE was ۱ (۰.۵۸%), ۳ (۱.۸۱%), and ۴ (۲.۴۲%) at ۶-, ۱۲-, and ۲۴-month follow-up, respectively. There were three cases (۱.۸۲%) of cardiac death and one case (۰.۶۱%) of ID-TLR up to ۲۴ months. None of the patients was presented with definite or probable stent thrombosis (ST).CONCLUSION: This study demonstrated that implantation of ultrathin strut Evermine ۵۰ EES resulted in a low rate of incidence of MACE, indicating a favourable clinical safety and performance profile of Evermine ۵۰ EES in patients with CAD [Clinical Trials Registry-India (CTRI) Number: CTRI/۲۰۱۷/۰۹/۰۰۹۹۳۹)].

Keywords:

Coronary Artery Disease , Drug-Eluting Stent , Everolimus , Percutaneous Coronary Intervention